Showing 5691-5700 of 5909 results for "".
- The Retina Group of Washington Will Merge With Maryland’s Retina Associateshttps://modernod.com/news/the-retina-group-of-washington-will-merge-with-marylands-retina-associates/2479714/The Retina Group of Washington (RGW), a leading provider of retinal and macular care in the Washington, D.C., metropolitan area, has announced plans to merge with Retina Associates (RA), a 5-office practice operating in suburban Maryland locations, according to a
- Nicox Postpones Nasdaq Listing Due to Market Volatilityhttps://modernod.com/news/nicox-postpones-nasdaq-listing-due-to-market-volatility/2479717/Nicox SA announced that due to the extreme volatility of the financial markets, it has decided to postpone its dual listing on Nasdaq, concluding that it would not be in the interest of their existing shareholders at this time, according to a company news release. The purpose of a Nasdaq l
- Report: Laser Vision Correction Procedure Volume Increases for Third Straight Yearhttps://modernod.com/news/report-laser-vision-correction-procedure-volume-increases-for-third-straight-year/2479719/Laser vision correction procedure volume in the United States increased for the third year in a row, indicating a growing demand for LASIK and other laser vision correction procedures, according to data released by the Refractive Surgery Council (RSC). Year-to-date laser vision correction
- Study: Diabetes Medication May Protect Against AMDhttps://modernod.com/news/study-diabetes-medication-may-protect-against-amd/2479722/Researchers from Taiwan have shown that people with type 2 diabetes who took a common diabetes medication, metformin, had a significantly lower rate of age-related macular degeneration (AMD). The study suggests that the anti-inflammatory and anti-oxidative effects
- Spectralis High Magnification Module Receives FDA Clearancehttps://modernod.com/news/spectralis-high-magnification-module-receives-fda-clearance/2479726/Heidelberg Engineering announced it has received FDA clearance for its Spectralis High Magnification Module. This new module consists of a highly innovative lens and software upgrade that will be available for new and
- New STAIRWAY Study Data Shows Potential for Extended Durability with Faricimab in Wet AMDhttps://modernod.com/news/new-stairway-study-data-shows-potential-for-extended-durability-with-faricimab-in-wet-amd/2479728/Genentech announced positive results from the phase 2 STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vi
- Easier, Potentially More Effective Treatment for Blinding Eye Disease Shows Promise in Clinical Trialhttps://modernod.com/news/easier-potentially-more-effective-treatment-for-blinding-eye-disease-shows-promise-in-clinical-trial/2479730/A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments. This represents a vast improvement over the typical regimen of nearly monthly eye injections. The researchers involve
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi
- Oyster Point Announces Positive Results From Two Phase 2b Clinical Trials of Investigational Treatments for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-positive-results-from-two-phase-2b-clinical-trials-of-investigational-treatments-for-dry-eye-disease/2479733/Oyster Point Pharma announced results from the ONSET and RAINIER studies, two separate phase 2b clinical trials evaluating the company’s novel therapies for the treatment of dry eye disease (DED). Both studies, presented at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrate
- CheckedUp Announces Expanding Reach in Vision Care and New Product Features at the Point of Carehttps://modernod.com/news/checkedup-announces-expanding-reach-in-vision-care-and-new-product-features-at-the-point-of-care/2479734/CheckedUp announced several new product features to optimize their health care decision technology. With more than 5,000 eye care professionals in the CheckedUp network, the technology empowers patients during their health care journey by engaging and educating them about their care, preventions,